Synektik Spólka Akcyjna stock
SNT.WAWSEHealthcareISIN PLSNKTK00019
78Score 78 out of 100, Strong
Price and trend
69 / 100
Price history
+27% in one yearThe chart shows daily closes over 15 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 5.4% above it.
Since October 2022 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 15% below its 52-week high. Largest decline in 15 years: 69% (March 2014 to January 2019).
Chart figures for advanced users
- SMA 50$85.30
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$79.98
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$60.99
- The lowest closing price of the last twelve months.
- Resistance$99.14
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Synektik Spólka Akcyjna belongs to the Medical (Devices) industry (Poland) and, with a market value of $718.95M, is number 70 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $171.43M (up 9.2% year on year) and earnings of $25.71M (up 20.7%).
- MEQIRI Score 78 out of 100 (Strong): rank 35 of 702 in Healthcare, median 53.
Show more
- The P/E is 16.1 (Medical (Devices) median 29.1, own median of recent years 21).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 81.8% in fiscal 2025, Medical (Devices) median 5.4%.Profitability 85
- Growing faster than its industryRevenue up 40.3% a year since 2020, Medical (Devices) median 13.8%.Growth 83
- Modestly valuedP/E 16.1, Medical (Devices) median 29.1, own median 21.Valuation 56
Weaknesses
- Margin may fall backOperating margin 23%, average of the prior years 9.6%, which ranged from 4.2% to 17.1%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.
Its standout strengths are profitability and capital allocation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 77 to 78.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
Valuation
Valuation signal
Fairly valuedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at more than four times the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 49.5% on the twelve months before. Revenue has grown strongly since 2010, at around 25% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 36%, operating 23%, net not measured.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 2 Dec 2026in 19 days
- Last reported
- 5 Aug 2026EPS reported $4.99
Analyst estimates
Analysts have raised their 2028 earnings estimate by 297.7% since 25 Oct 2026.
- Earnings per share
- $22.40+292.7%
- Revenue
- $246.84M−0.8%
- Earnings per share
- $26.41+297.7%
- Revenue
- $280.26M−0.2%
MEQIRI has stored the estimates since 25 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Synektik Spólka Akcyjna
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 78
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Delcath SystemsDCTH $743.77M64
- BioventusBVS $743.63M60
- Beta BionicsBBNX $742.78M46
- Cytek BiosciencesCTKB $721.93M46
- Senseonics HoldingsSENS $659.99M44
- Xvivo PerfusionXVIVO.ST $640.54M50
- Pacific Biosciences of CaliforniaPACB $612.34M35
- Sight SciencesSGHT $610.81M48
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Sep 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = PLN 3.9742)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Jan 2024)
- Valuation signal Fairly valued since 8 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.